Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Liminal BioSciences stock | $4.42

Learn how to easily invest in Liminal BioSciences stock.

Liminal BioSciences Inc
NASDAQ: LMNL - USD
BIOTECHNOLOGY
$2.95
+$0.01 (+0.35%)

Liminal BioSciences Inc is a biotechnology business based in the US. Liminal BioSciences shares (LMNL) are listed on the NASDAQ and all prices are listed in US Dollars. Liminal BioSciences employs 251 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Liminal BioSciences

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LMNL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Liminal BioSciences stock price (NASDAQ: LMNL)

Use our graph to track the performance of LMNL stocks over time.

Liminal BioSciences shares at a glance

Information last updated 2021-07-23.
Latest market close$4.42
52-week range$3.27 - $24.56
50-day moving average $4.03
200-day moving average $4.50
Wall St. target price$3.61
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-12.81

Buy Liminal BioSciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Liminal BioSciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Liminal BioSciences price performance over time

Historical closes compared with the close of $4.42 from 2021-05-28

1 week (2021-07-19) N/A
1 month (2021-06-30) 13.62%
3 months (2021-04-30) -12.13%
6 months (2021-01-26) N/A
1 year (2020-07-26) N/A
2 years (2019-07-26) N/A
3 years (2018-07-26) N/A
5 years (2016-07-26) N/A

Liminal BioSciences financials

Revenue TTM $3.3 million
Gross profit TTM $-55,542,000
Return on assets TTM -46.55%
Return on equity TTM -349.85%
Profit margin 0%
Book value $0.12
Market capitalisation $98.2 million

TTM: trailing 12 months

Shorting Liminal BioSciences shares

There are currently 442,308 Liminal BioSciences shares held short by investors – that's known as Liminal BioSciences's "short interest". This figure is 4.8% up from 421,885 last month.

There are a few different ways that this level of interest in shorting Liminal BioSciences shares can be evaluated.

Liminal BioSciences's "short interest ratio" (SIR)

Liminal BioSciences's "short interest ratio" (SIR) is the quantity of Liminal BioSciences shares currently shorted divided by the average quantity of Liminal BioSciences shares traded daily (recently around 2.5 million). Liminal BioSciences's SIR currently stands at 0.18. In other words for every 100,000 Liminal BioSciences shares traded daily on the market, roughly 180 shares are currently held short.

However Liminal BioSciences's short interest can also be evaluated against the total number of Liminal BioSciences shares, or, against the total number of tradable Liminal BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Liminal BioSciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Liminal BioSciences shares in existence, roughly 10 shares are currently held short) or 0.0543% of the tradable shares (for every 100,000 tradable Liminal BioSciences shares, roughly 54 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Liminal BioSciences.

Find out more about how you can short Liminal BioSciences stock.

Liminal BioSciences share dividends

We're not expecting Liminal BioSciences to pay a dividend over the next 12 months.

Have Liminal BioSciences's shares ever split?

Liminal BioSciences's shares were split on a 1:1000 basis on 4 July 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Liminal BioSciences shares – just the quantity. However, indirectly, the new 99900% higher share price could have impacted the market appetite for Liminal BioSciences shares which in turn could have impacted Liminal BioSciences's share price.

Liminal BioSciences share price volatility

Over the last 12 months, Liminal BioSciences's shares have ranged in value from as little as $3.27 up to $24.56. A popular way to gauge a stock's volatility is its "beta".

LMNL.US volatility(beta: 1.44)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Liminal BioSciences's is 1.4431. This would suggest that Liminal BioSciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Liminal BioSciences overview

Liminal BioSciences Inc. , a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma-Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050), which is in Phase 1 for the treatment of idiopathic pulmonary fibrosis and respiratory diseases. The Plasma-Derived Therapeutics segment focused on the development of its plasma-derived product candidate Ryplazim, a purified glu-plasminogen derived from human plasma that acts as a plasminogen replacement therapy for patients deficient in plasminogen protein. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc.

Frequently asked questions

What percentage of Liminal BioSciences is owned by insiders or institutions?
Currently 66.404% of Liminal BioSciences shares are held by insiders and 0.248% by institutions.
How many people work for Liminal BioSciences?
Latest data suggests 251 work at Liminal BioSciences.
When does the fiscal year end for Liminal BioSciences?
Liminal BioSciences's fiscal year ends in December.
Where is Liminal BioSciences based?
Liminal BioSciences's address is: 440 Boulevard Armand-Frappier, Laval, QC, Canada, H7V 4B4
What is Liminal BioSciences's ISIN number?
Liminal BioSciences's international securities identification number is: CA53272L1031
What is Liminal BioSciences's CUSIP number?
Liminal BioSciences's Committee on Uniform Securities Identification Procedures number is: 53272L103

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site